To further elucidate the clinical efficacy and safety of a combination regimen based on the BTK inhibitor zebutanil bridging CD19 Chimeric antigen receptor T cells(CAR-T cells)in the treatment of relapsed/refractory diffuse large B-cell lymphoma(r/r DLBCL). The gene discussed is BTK; the disease is diffuse large B-cell lymphoma.